1. OLISTAT PELLETS 50% 2.  COMPANY PROFILE  Murli Krishna Pharma is an EU-GMP/ WHO-GMP and PIC/S approved plant.  We manufacture pre finished formulation intermediates…

Slide 1AXINN, VELTROP & HARKRIDER LLP © 2007 | www.avhlaw.com AXINN, VELTROP & HARKRIDER LLP Click To Modify Title Name Goes Here FDA Hearings on the BPCI Act Chad…

ASEAN GUIDELINES FOR THE CONDUCT OF BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES FINAL DRAFT : 21 JULY 2004 Adopted from the “NOTE FOR GUIDANCE ON THE INVESTIGATION OF BIOAVAILABILITY…

1. Second and further medical use patents: enforcement perspectiveDr Duncan Curley Director and Head of Patents, Innovate Legal C5 Pharma & Biotech Patent Litigation…

1. Global Oncology Biosimilars Market 2014-2018 TechNavio Insights 2. USA – CANADA – UK – CHINA – INDIA Market Overview: Oncology…

Slide 1 FLEXTEK Slide 2 THE TECHNOLOGY Flextek is a bi-fuel converter which allows your car to work using alcohol, gasoline or a mixture of both. An innovator product on…

Slide 1 Fordham IP Conference 9 April, 2015 - Cambridge Biosimilar Patent Litigation – UK Perspective Dr Penny Gilbert Powell Gilbert LLP 1 Slide 2 A changing landscape.…

Slide 1 1 Expert Opinion: Are Biosimilars really Generics ? “ A Compliant Cold Chain Management for the Integrity of Biological Products” Cyril Chaput, Ph.D. Alternatives…

Slide 1 Slide 2 1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri Slide 3 2 FDA Thailand Introduction Drugs registration The effect of FDA on Marketing…

1-7.The ICH Q8 âMinimal Approachâ to Pharmaceutical Development Satish Mallya January , 2011 Satish Mallya January 20-22, 2010 * | Pharmaceutical Development Q8(R2) The…